Innovative Urgency Urinary Incontinence Treatment Investment

News Summary

Valencia Technologies, a California-based medical device firm, has raised $35 million from Brooks Advisory Group to enhance the commercialization of its eCoin system for treating urgency urinary incontinence (UUI). The company appointed James D. Surek as CEO, leveraging his extensive medical device experience. The FDA-approved eCoin device, a minimally invasive tibial nerve stimulator, significantly reduces UUI episodes. This strategic investment supports Valencia’s growth, capitalizing on the increasing demand for minimally invasive treatment options.

California – Valencia Technologies, a California-based medical device company, has secured a strategic investment of up to $35 million to advance its efforts in treating urgency urinary incontinence (UUI). The investment is provided by Brooks Advisory Group, part of the broader Brooks Management Group (BMG), and aims to accelerate the commercialization of the company’s innovative eCoin® system.

Alongside this substantial investment, Valencia Technologies has appointed James D. Surek as its new Chief Executive Officer (CEO). Surek comes to the role with a wealth of experience in the medical device sector, having previously driven significant revenue growth at multiple organizations.

The eCoin system is at the forefront of Valencia Technologies’ offerings, having gained FDA approval in 2022. This device is unique as it is the first and only FDA-approved implantable tibial nerve stimulator designed specifically for treating UUI through a minimally invasive outpatient procedure. The eCoin device, about the size of a coin, is implanted under the skin near the ankle and works by delivering periodic stimulation to the tibial nerve twice a week. Clinical data suggests that this treatment leads to a reduction of urge urinary incontinence episodes by at least 50% for 75% of patients at the one-year mark.

The investment from Brooks Advisory Group not only provides capital but also includes valuable consulting services aimed at enhancing commercialization strategies. These services will assist Valencia Technologies in navigating sales, reimbursement, payor relations, and financial strategies as it brings the eCoin system to market.

Valencia Technologies’ management team is further strengthened by the appointment of Surek, who has a proven track record in revenue growth and turnarounds. Specifically, at Advanced Bionics, he played a pivotal role in growing revenues from $50 million to over $200 million within three years, culminating in the company’s acquisition by Boston Scientific for approximately $3 billion. Additionally, his leadership helped Entellus Medical grow its revenue from less than $1 million to over $70 million, achieving an IPO in less than four years.

Dr. Jason Kim from Stony Brook Medicine has criticized traditional treatment options for UUI, praising the eCoin system instead as an effective alternative to medications and more invasive procedures. The device’s design streamlines the post-implant experience, reducing the frequency of follow-up programming sessions and eliminating the need for weekly recharging of the device.

The strategic moves by Valencia Technologies align with an increasing demand for minimally invasive treatment options in the medical industry, particularly in managing conditions that can substantially affect the quality of life for many patients. With the backing of a significant financial investment and experienced leadership, the company is well-positioned to make strides in expanding access to the eCoin system, ultimately aiming to improve the lives of those suffering from UUI.

As Valencia Technologies continues to move forward with its plans, the combination of innovative technology and strong leadership under Surek may set new standards in the treatment of urgency urinary incontinence, paving the way for future advancements in the field of neuromodulation.

Valencia Technologies Secures $35M Investment for UUI Treatment

News Summary

Deeper Dive: News & Info About This Topic

Author: HERE LOS ANGELES